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Purpose: The proliferation of arterial-wall smooth muscle cells is an important step in the 
formation of intimal hyperplasia. Insulin-like growth factor-I (IGF-I) is a mitogen that 
exerts its effects through specific receptors located on the cell membrane. IGF-I has been 
found to promote the multiplication ofvas~axlar smooth muscle cells in culture. This study 
aimed to evaluate the status of IGF-I binding in injury-induced intimal hyperplasia in a 
rabbit model. 
Methods: We used binding techniques to study IGF-I binding of control and hyperplastic 
aortas of adult White New Zealand rabbits. Hyperplasia was induced by balloon-catheter 
injury. At 2 weeks and 1, 2, 4, and 7 months after injury, segments of abdominal aortas 
were harvested from two control and six study rabbits, and 20-~tm-thick frozen sections 
were obtained. Hematoxylin and eosin-stained sections confirmed the presence of intimal 
hyperplasia in the hyperplastic aortas. Adjacent sections were incubated ina buffer solution 
containing 12sI-IGF-I in the presence and absence of an excess of unlabeled IGF-I. 
Autoradiograms were then obtained by apposing the treated sections to autoradiography 
film, which was developed at 3 days and analyzed by comparison with the hematoxylin and 
eosin-stained sections under light microscopy. A marked increase in IGF-I binding grain 
density was observed inthe areas corresponding to the hyperplastic lesions. To characterize 
these binding sites, binding inhibition studies were performed and the dissociation 
constant (Kd) and maximum binding capacity (Bmax) were obtained from Scatchard 
analysis. 
Results: Six hyperplastic aortas for each time interval and a total of nine control aortas were 
evaluated. The K d of the hyperplastic aortas (1.5 -+ 0.2 nmol/L) was not significantly 
different from that of control aortas (1.3 -+ 0.2 nmol/L), which indicated similar 
high-affinity IGF-I binding sites in normal and hyperplastic arteries. The results of Bma x 
were 6.9 -+ 1.2, 8.5 -+ 2.1, 12.4 -+ 2.1, 20.4 - 5.9, 20.6 -+ 3.2, and 8.1 -+ 1.3 pmol/L 
for control, 2 weeks, 1 month, 2 months, 4 months, and 7 months, respectively. With 
analysis of variance (p < 0.05), gma xvalues at 1, 2, and 4 months were significantly higher 
than those of control aortas. Bma xvalues returned to levels not significantly different from 
those of control aortas at the 7-month interval. 
Conclusion: Increased IGF-I binding in the hyperplastic aortas uggests that IGF-I plays 
an important role in the proliferation of arterial wall cellular components during the 
hyperplastic process. (J VASC SURG 1996;23:308-13.) 
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Intimal hyperplasia is a prolifcrative process that 
causes thickening of the arterial wall in response to 
injury, such as balloon angioplasty or placement of a 
bypass graft) ,2 Intimal hyperplasia is the primary 
cause of restenosis after peripheral or coronary 
angioplasty. ~ The hyperplastic lesion is formed 
mainly of proliferating vascular smooth muscle cells.1 
Growth factors are peptide molecules that influence 
the growth and multiplication of human cells. 
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Insulin-like growth factor-I (IGF-I), a potent mito- 
gen, was found to promote the growth of cultured 
smooth muscle cells. 4's IGF-I, like many other 
growth factors, exerts its effects via specific receptors 
located on the cellular membrane. These receptors 
belong to the tyrosine kinase group. 6The interaction 
of various growth factors with their specific receptors 
causes a series of intracellular biochemical reactions 
that result in the specific effects of growth factors. 7 
We have characterized IGF-I receptor binding in fro- 
zen sections of normal arteries of the rabbit. IGF-I 
had a high-affinity specific binding site with a disso- 
ciation constant (Kd) of 2 nmol/L. 8 In this study we 
attempt to determine the in-situ localization oflGF-I 
binding in rabbit aortas with injuryqnduced intimal 
hyperplasia, nd to assess IGF-I binding in the con- 
trol and hyperplastic aortas in various postinjury in- 
tervals. 
MATERIALS AND METHODS 
Adult white New Zealand rabbits were anesthe- 
tized with xylazine (17 mg/kg) and ketamine (83 
mg/kg) and underwent surgery under sterile surgical 
conditions. Ten served as the control group and had 
the right femoral artery exposed and tied off without 
introduction of a catheter. The remaining 30 rabbits 
(hyperplastic group) had the femoral artery exposed 
and opened transversely. A 3F balloon Fogarty cath- 
eter was introduced proximally to a location in the 
upper abdominal aorta, inflated to 3 atmospheric 
pressures, and pulled out to the femoral artery. This 
process was repeated three times in each of the hyper- 
plastic study rabbits. The femoral artery was then tied 
off, and the skin incision was closed. After recovery 
from surgery, all rabbits were fed regular abbit food 
for the duration of the study. Animal subjects were 
treated according to The Guide For Care And Use of 
Laboratory Animals. 9The abdominal aorta was har- 
vested from two control and six hyperplastic rabbits 
at 2 weeks and at 1, 2, 4, and 7 months after injury. 
The specimens were flushed with iced saline at 4 ° C, 
frozen immediately on dry ice, embedded in gelatin, 
and stored at - 70 ° C. The tissues were then studied. 
Autoradiographic studies. Autoradiography 
was used to delineate the in-situ distribution of 
IGF-I binding sites in the wall of normal and 
hyperplastic aortas and in the hyperplastic lesions. 
Twenty-~m-thick frozen sections were cut and 
mounted on slides. Sections were stained with 
hematoxylin-and-eosin (H&E) stain, and the pres- 
ence of the hyperplastic lesions in the study rabbits 
was confirmed with light microscopy. To obtain 
total binding, adjacent sections mounted on slides 
were incubated in 3.2 ml of buffer solution contain- 
ing 10 mmol/L N-2-hydroxyethylpiperazine-N-2- 
ethanesulfonic a id (pH, 7.6), 130 mmol/L NaC1, 
4.7 mmol/L KC1, 5 mmol/L MgC12, 1 mmol/L 
ethyleneglycol-bis- ([3 aminoethylether)-N,N,N',N'- 
tetraacetic acid, 0.5% bovine serum albumin, 
0.025% bacitracin, 0.0125% N-ethylmaleimide 
(Sigma Chemical; St. Louis), 100 KIU/ml aprotinin 
(FBA Pharmaceuticals; New York), and 40 pmol/L 
125I-IGF-I (Amersham; Arlington Heights, Ill.) at 
4 ° C. Nonspecific binding was assessed by incubating 
adjacent sections for 24 hours in the same buffer 
solution but with 0.1 ~tmol/L of unlabeled IGF-I or 
10 ~mol/L insulin (Eli Lilly; Indianapolis) to com- 
pete with 125I-IGF-I for its binding sites. The un- 
bound radiolabeled peptide was removed by washing 
the slides in ice-cold 10 mmol/L phosphate-buffered 
saline (pH, 7.4) at the end of the incubation. The 
total and nonspecific binding autoradiographs were 
obtained by placing the slides in an X-ray cassette in 
tight apposition to a Hyperfilm-3H (Amersham). 
This part of the procedure was performed in a dark- 
room, and the slides were kept in tight apposition to 
the film for 3 days. The film was then developed with 
D19 developer and fixed in Rapidfix (Eastman 
Kodak, Rochester, N.Y.). The total binding autora- 
diographs were compared with corresponding H&E- 
stained slides and nonspecific binding autora- 
diographs using light microscopy. 
Binding studies. To determine IGF-I binding 
in various postinjury intervals, binding inhibition 
studies were performed on control and hyperplastic 
aortas. The slides were incubated for 24 hours in 
the same buffer solution containing 40 pmol/L of 
~25I-IGF-I used for the autoradiography studies; 
however, increasing concentrations of the unlabeled 
IGF-I were added. At the end of the incubation 
period, instead of exposing the slides to the au- 
toradiography film, they were dried and the sections 
were wiped off. The bound labeled peptide in the 
sections was counted in a gamma counter. Each 
experiment was performed three times, and an 
average was obtained from the results of the three 
experiments. Analysis of the data was performed 
with the Curve Fitting and Data Analysis Ligand 
Binding program (version 3.10, National Institutes 
of Health, Bethesda, Md.). The values of maximum 
binding capacity (Bm~,,) and Kd for each hyperplastic 
and control aorta were obtained. 
RESULTS 
The presence or absence of intimal hyperplasia 
was confirmed with light microscopy. The control 
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Fig. 1. A, H&E-stained section 1 month after balloon-catheter injury demonstrating abdomi- 
nal aorta with intimal hyperplasia (h) media (m), and adventitia (a). B, Autoradiograph of 
sequential section demonstrating 125I-IGF-I total binding to areas corresponding tolocation of 
media and intimal hyperplasia. C, Autoradiograph ofsequential section demonstrating absence 
of nonspecific binding of 12q-IGF-I, which confirms specificity of these binding sites to IGF-I. 
aortas were devoid of hyperplastic lesions; intimal 
hyperplasia was found in the wall of the study aortas 
(Fig. la). One control rabbit died during the course 
of the study, resulting in 9 control aortas for the 
study. Of  the 30 hyperplastic study rabbits, 6 were 
used in each of the 5 time intervals. 
Binding localization. Autoradiography was 
used to delineate binding localization on frozen 
sections of the control and hyperplastic aortas. This 
method is valuable because it gives a representation 
of the binding in situ rather than i the environment 
of cell culture. Therefore, by comparison with 
H&E-stained adjacent sections, the localization of 
125I-IGF-I binding to the arterial wall or to a certain 
lesion of the wall can be determined. 1° In normal 
aortas, 125I-IGF-I binding was localized to the 
arterial wall; the same was found in an earlier study.* 
It is difficult to ascertain whether there was any 
binding to the intima due to the decreased thickness 
of this layer in normal arteries. In addition to the 
125I-IGF-I binding present in the wall of  the study 
aortas, however, binding was also localized to the 
hyperplastic lesions occupying the subendothelial 
area (Fig. lb). The presence of 125I-IGF-I binding 
was consistent; it was found in every hyperplastic 
lesion studied. The binding was specific to IGF-I; an 
excess of unlabeled IGF-I almost completely dis- 
placed 125I-IGF-I from its binding sites in the arterial 
wall and hyperplastic lesions (Figs. lb, lc, 2a, 2c). 
Insulin, however, was partially able to compete with 
125I-IGF-I for its binding sites (Fig. 2a and 2b) de- 
spite that 100-fold more insulin was added to the 
buffer (10 Ixmol/L) than unlabeled IGF-I (0.1 
Ixmol/L). This finding demonstrated that these bind- 
ing sites were specific for IGF-I and not insulin. 
Affinity and Bin,,,. The affinity of the receptor to 
its ligand is determined by K a. The K d value of all 30 
hyperplastic aortas (1.5 + 0.2 nmolfL) was not 
significantly different from that of the 9 control 
aortas (1.3 ___ 0.2 nmol/L). In addition, when the K a 
value from the hyperplastic aortas from each time 
interval was compared with that of the control aortas, 
there was again no significant, difference, indicating 
similar high-affinity IGF-I binding in both normal 
and hyperplastic arteries. 
To evaluate the capacity of the binding, values for 
Bma x in control and hyperplastic arteries were ob- 
tained. Although Bma x at 2 weeks was increased in the 
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Fig. 2. A, Autoradiograph of a section of hyperplastic aorta 1 month after balloon-catheter 
injury demonstrating total 12sI-IGF-I binding grain density. B, Nonspecific binding for insulin. 
An excess of insulin (10 ixmol/L) was used to compete with 12sI-IGF-I for its binding sites. Note 
high concentration f nonspecific binding. C, Nonspecific binding for IGF-I. An excess of 
unlabeled IGF-I (0.1 ixmol/L) was used to compete with 12sI-IGF-I for binding sites. Note 
difference in nonspecific binding between B and C despite using 100-fold more insulin than 
unlabeled IGF-I to inhibit t2sI-IGF-I binding. 
hyperplastic arteries when compared with control 
arteries, the increase was not statistically significant 
(8.5 +_ 2.1 compared with 6.9 _+ 1.2 pmol/L, 
p = NS). The increase in IGF-I gma x was  significant 
at i, 2, and 4 months (12.4 +- 2.1, 20.4 _+ 5.9, and 
20.6 _+ 3.2 pmol/L, respectively, p < 0.05 for each 
time interval using analysis of variance) when com- 
pared with control arteries (6.9 _+ 1.2 pmol/L). At 7 
months (8.1 +- 1.3 pmol/L) Bm~ , returned to levels 
not significantly different from those of control 
arteries (Fig. 3). This data indicated that IGF-I 
binding increased in the hyperplastic arteries. The 
increase in binding reached its peak at 2 and 4 months 
before decreasing to control levels at 7 months. 
DISCUSSION 
Intimal hyperplasia is a proliferative disease of the 
vascular wall. In response to injury, arterial smooth 
muscle cells, especially those of the media, proliferate 
and migrate to the subendothelial rea to form the 
hyperplastic lesion. If  the injury continues, the 
hyperplastic lesion thickens until it completely oc- 
cludes the arterial umen, resulting in arterial insuffi- 
ciency.~ Peptide growth factors have been found to 
influence the proliferation of animal cells, including 
arterial smooth muscle cells. Cells are usually found 
in a resting quiescent phase (G o phase). To multiply, 
the cell enters a specific cycle. Peptide growth factors 
are divided into two groups by their effects on the 
progression of the cell cycle. 7 Competence factors 
that advance the quiescent cell from the G o to the G l 
phase (the first gap phase) include platelet-derived, 
fibroblast, and epidermal growth factors; and pro- 
gression factors such as IGF-I and insulin that 
commit the cell to the synthesis of DNA by 
advancing the cell from G 1 phase to S phase (DNA 
synthesis and chromosome replication). To keep the 
cell progressing in the G 1 phase, simultaneous 
stimulation by both groups of factors is needed. 6 
Because IGF-I exerts metabolic effects similar to 
those of insulin and shares sequence homology with 
insulin, it was given the name "insulin-like. ''n IGF-I 
exerts its mitogenic effects through a specific tyrosine 
kinase receptor located in the cell wall known as 
type-1 IGF receptor or IGF-I receptor. 6 This receptor 
binds IGF-I with high affinity, resulting in a K a value 
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Fig. 3. Comparison ofBma xof~2sI-IGF-I binding of 9 control aortas overall and 6 hyperplastic 
aortas per time interval at 2 weeks and at 1,2, 4, and 7 months after injury. *p < 0.05 with 
analysis of variance test when mean ofBm~ x of each time interval is compared to that of controls. 
of about 1.5 nmol/L. 8~2,13 Although the molecular 
structure of the IGF-I receptor resembles that of the 
insulin receptor, the IGF-I receptor interacts weakly 
with insulin. Both the insulin and the IGF-I receptors 
are organized as heterotetramer, with two ~x and two 
[3 binding subunits. The two receptors can be 
distinguished from each other by ligand binding 
affinity. The IGF-I receptor has more affinity for 
IGF-I than for insulin, whereas the insulin receptor 
has much more affinity for insulin.14 In this study, the 
high affinity of the binding to IGF-I, as indicated by 
the K a value of 1.3 _+ 0.2 nmol/L for control aortas 
and 1.5 + 0.2 nmol/L for hyperplastic aortas, was 
comparable with previously published K d values of 
IGF-I binding. 8,12,13 This similarity indicated the 
presence of a single-class high-affinity IGF-I binding 
in control and hyperplastic aortas. In addition, the 
in-situ distribution of binding was elucidated with 
autoradiography. IGF-I binding was localized to the 
arterial wall and to the hyperplastic lesions. This 
binding was specific to IGF-I because the addition of 
an excess of the unlabeled peptide successfully 
competed with ~2sI-IGF-I for these binding sites. The 
same was also shown in earlier eports with autora- 
diography and binding inhibition studies. 8,12 
The interaction between a growth factor and its 
binding site is the first step in expressing the effect of 
the growth factor; therefore, the presence of those 
binding sites in a tissue indicates that the growth 
factor plays a role in the maintenance and prolifera- 
tion of the cellular component in that particular 
tissue, is Thus whether IGF-I is produced here by 
arterial-wall cellular components 16 or in the liver, 
where it is produced in abundanc@ 7 the presence of 
IGF-I binding sites in the wall of the artery suggests 
that IGF-I plays a role in the proliferation of the 
arterial-wall cellular components. In this study, IGF-I 
binding was found in the hyperplastic lesions, and the 
Bm,~ in the hyperplastic arteries howed an increasing 
trend that became significant at 1, 2, and 4 months, 
then returned to values not significantly different 
from those of control arteries at 7 months after 
injury. It has been reported that balloon-catheter 
injury to the endothelium resulted in an increase in 
the local production of IGF-I, as evidenced by the 
increase in the synthesis of IGF-I mRNA)  6 The 
results of our study further suggest the importance of 
the role played by IGF-I; not only IGF-I production 
itself is increased in response to injury, 16 but the 
capacity of its binding sites also increases. 
These results are shown in hyperplastic tissue in 
situ rather than in a cell-culture nvironment. Be- 
cause transferring dynamic disease conditions to a 
cell-culture nvironment can be a difficult ask, these 
results, especially that autoradiography demonstrated 
the distribution of the binding sites to be in the 
hyperplastic lesion in addition to the remaining 
arterial wall, gain more importance. Although it has 
been reported that little smooth musclc cell acctunu- 
lated in intimal hyperplasia beyond 1 month after 
injury, 18 our study shows that Bm. x remained high up 
to 4 months after injury. This observation can be 
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explained by the different arteries and animal models 
used in the two studies; the carotid artery of the male 
Sprague-Dawley rat and the aorta of the male white 
New Zealand rabbit, respectively. The rabbit aorta is 
a higher-flow artery, its wall is submitted to higher 
shear stress, and therefore amore severe or prolonged 
injury ensues. It has been shown that occlusion of one 
femoral artery resulted in increased IGF-I immunore- 
activity in the media of the contralateral femoral 
artery, presumably because of increased wall tension 
in response to increased vascular load. t9 This finding 
may explain the maintained increase in IGF-I binding 
in rabbit hyperplastic aortas beyond the time when 
smooth muscle accumulation in injured rat carotid 
artery was shown to have ceased. ~s 
The increase in IGF-I binding capacity can be 
explained by an increase in the number of smooth 
muscle cells in the lesion, rather than the increase in 
the number of binding sites per cell. The demonstra- 
tion of high-affinity IGF-I binding sites in the intimal 
hyperplastic lesions in addition to the arterial wall, 
however, suggests that IGF-I plays an important role 
in the proliferation of arterial smooth muscle cells 
during the hyperplastic process. Blocking these ty- 
rosine kinase binding sites or their signaling path- 
ways may prove important in controlling the progres- 
sion of the hyperplastic process. An array of com- 
pounds that block the binding of growth factors to 
their tyrosine kinase receptors is currently being de- 
veloped. Some can block virtually every known step 
of the intraceUular signaling process. 2° Growth fac- 
tor-receptor blockade with specific receptor antibod- 
ies can be used to inhibit the binding of a growth 
factor to its specific receptor. Because of the syner- 
gism among growth factors in their effect on the cell 
cycle, 7,21 however, it is important to remember that 
any therapy may need to be directed towards multiple 
growth factor binding sites. Materials that inhibit the 
binding of growth factors to their tyrosine ldnase 
receptors in general have been developed, and some 
compounds have shown benefit in the treatment of 
other proliferative diseases affecting cell growth and 
proliferation. 20,22 
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